GlaxoSmithKline has triggered an option under a 1996 joint partnership deal with Human Genome Sciences to co-develop LymphoStat-B, an experimental drug for rheumatoid arthritis. The two companies will split the costs of Phase III and Phase IV trials and share in the revenues from any successful product launch.
- read this report from the Washington Business Journal for more